{
  "ticker": "4DX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959035",
  "id": "02959035",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250617",
  "time": "0853",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kt90g6gt5z3c.pdf",
  "summary": "- **Contract Expansion with Stanford University**:  \n  - Renewed and expanded 1-year subscription agreement, including **CT:VQ\u2122** (pre-FDA clearance for research/evaluation).  \n  - Also licenses **CT LVAS\u2122** and **IQ-UIP\u2122** (already FDA-cleared).  \n  - Supports up to **20,000 CT scan analyses annually**.  \n\n- **Strategic Significance**:  \n  - Stanford\u2019s adoption of CT:VQ\u2122 ahead of FDA clearance validates market potential.  \n  - Strengthens clinical validation and U.S. market readiness for 4DMedical\u2019s pipeline.  \n\n*No capital raising, financials, or trading halt details provided*.",
  "usage": {
    "prompt_tokens": 1489,
    "completion_tokens": 143,
    "total_tokens": 1632,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T23:00:33.355610"
}